Guardant Health, Inc. NMS · GH

$151.91 +3.84 (+2.59%)

Neutral · +0.03σ

+ Compare Open in Sniper

Mkt cap $20.1B

P/E —

Day $144.89 – $152.73

52wk $74.55 – $174.08

Avg vol 2.7M

Beta 1.59

Div yld —

Next earnings 2026-07-30

Quick read

Plain English

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.

GH last traded at $151.91, up 2.6% on the day; that's in the upper part of its 52-week range ($74.55–$174.08). Right now it's trading close to its recent average, with no strong stretch in either direction.

The next scheduled earnings report (2026-07-30) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

above KC1 lower, -0.03 ATR from EMA21 — no notable pattern

Long —

score 16 · tech 16 / 80 · support 0 / 20

above KC1 lower, -0.03 ATR from EMA21 · no notable pattern

· Aligned with breakout up (strong tailwind)

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 6 · tech 6 / 80 · support 0 / 20

below KC1 upper, -0.03 ATR from EMA21 · no notable pattern

· Counter-trend short in breakout up

How this grade was earned

total 6 pts

Cycle position 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Fair-value range

$22.22 – $22.22

Verdict

Unknown

Accounting quality Weak

✓ Quick ratio 4.08 (antifragile)
✓ Current ratio 4.84 (antifragile)
✓ Goodwill 4% of assets (organic growth)
✓ Gross margin 65% (pricing power)

⚠ Debt exceeds cash
⚠ Negative retained earnings
⚠ Stock comp 17% of revenue (heavy dilution)

Key statistics

All statistics →

GH is a $20.1 billion company, it moves harder than the market (beta 1.6).

Mkt cap $20.1B

P/E ttm —

Fwd P/E -350.7

Beta 1.59

Day range $144.89 – $152.73

52w range $74.55 – $174.08

Avg vol 2.7M

RSI(2) 46.5

ROE —

Net mgn -40.1%

FCF mgn -7.9%

Debt/Eq —

Div yld —

Sector Healthcare

Industry Diagnostics & Research

Next earn 2026-07-30

52-week range · today's price

$74.55$174.08

More on GH

Options idea

See more →

CALL $150 2026-08-21

$13.13

PUT $155 2026-08-21

$14.51

Earnings

See more →

Last reported: 2026-05-07
EPS (act / est): -0.45 / -0.47
Surprise: +5.0%
Next report: 2026-07-30

About

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that util…